N
Google TrendPANTHERS VS BLUE JACKETS (200+) — Gameday 7: Florida Panthers at Columbus Blue Jackets
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:panthers vs blue jackets200+posiciones de atlético de madrid contra manchester united5000+devils vs red wings2000+lioness season 35000+tresoldi200+street fighter movie early reviews2000+luis díaz200+halle berry child custody hearing200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Epcoritamab Plus R2 in Fo" (26 stories)

Top Headline Story

Epcoritamab Plus R2 in Follicular Lymphoma: A Potential New Treatment Standard
Lead StoryThe ASCO Postgeneral
Feb 25

Epcoritamab Plus R2 in Follicular Lymphoma: A Potential New Treatment Standard

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxQUzVXZ1lMdElHWTIwMzVSZ1VYWkdqR2pNTkVQaFVZbFVGWWtSVEhHd3Z6Vk9VMnhXZXFLd05JcldLYVpxcGV5YWwtZFdmcVNWOUYycVp5ZDk5TlFYeWUtN1hKdExtUVczc3JoMm51dEppcWs0NG40Q25RRW9UcEtKdGl1d3pkSjVlWmt0d0lidzRXMXhRaXI2Q3RKTGVuOWZFSldab3FxNFpZNHBhRmUxVlNJWkRJbUY0WnFrSGpmdWdLdkJJSlFaMzIzOXA0RWl1cjFlV2psaVVZcWlTdTc1YzVpY0VJdGdCWVZzd0FKVm4tbkxi?oc=5" target="_blank">Epcoritamab Plus R2 in Follicular Lymphoma: A Potential New Treatment Standard</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
200+22m ago

panthers vs blue jackets

Gameday 7: Florida Panthers at Columbus Blue Jackets

Filter stories
5000+32m ago

posiciones de atlético de madrid contra manchester united

La quinta para el 6

Filter stories
2000+32m ago

devils vs red wings

Roster Changes for Devils vs. Red Wings | PREVIEW | New Jersey Devils

Filter stories
5000+32m ago

lioness season 3

Thank Zoe Saldaña for ‘Lioness’ Season 3’s Perfect Cliff-Hanger

Filter stories

Search Results for "Epcoritamab Plus R2 in Fo"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

25 stories displayed
Epcoritamab/R2 Earns European Approval for R/R Follicular Lymphoma
CancerNetworkworld

Epcoritamab/R2 Earns European Approval for R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPV2dCcF9EUGhlNnBHRkZybXBzLWFyelZwY3RjQlpOU2pDTVFsWlItRjktYkxheDVqMnpFSTlBU1N2RFJSS2M0MkoyM3FiWXdoUUI2THlrem5iaTd6eW1kb211UTJqQnU2R3NaMnN1cy13Zk8wYndBM0xvcVFsM01pYXBka3dLV0xhZEN3Wi1aZ3Q5SGpaWUotVWFXMFNUWVQ5OVRR?oc=5" target="_blank">Epcoritamab/R2 Earns European Approval for R/R Follicular Lymphoma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Epcoritamab Plus Lenalidomide/Rituximab Wins EU Approval for R/R Follicular Lymphoma
OncLivegeneral

Epcoritamab Plus Lenalidomide/Rituximab Wins EU Approval for R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPMlgtRU9GT0dva1NJaTlkbElsVW9fQTdSOVA5SUZJaUFnTHhMbVppSUJXTDhNWUsxTVN2NG1RLVBCcW1RR0Itd25yOS1RcFA0QnkyQWV0UjBEeW9COVdRVXFhclU2TkFsTEdTLU9td3l6R0VOd2RLV1VVeGVLYlhoOUZUX2FEcU8wbENVR1NEUThLUmJGaHUwekVDSm9HRGZPTXlMQ295aVVNdUE5YTgydUhR?oc=5" target="_blank">Epcoritamab Plus Lenalidomide/Rituximab Wins EU Approval for R/R Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Epcoritamab Plus Lenalidomide and Rituximab in Practice: A Focus on EPCORE FL-1
Pharmacy Timesgeneral

Epcoritamab Plus Lenalidomide and Rituximab in Practice: A Focus on EPCORE FL-1

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQaXloVTJxTk52eW1lNzVMdW93SU1vMm8yTE5WQXgxTkRNUS1vYUpjU2M0cW1qeDdoQU90OVZJc295WUtiUGt5cXpSMUQxaFBGMG5wUGZJTkt0NFNodi11RWwzWUNFVG5BY1hpREhoOXgwalMxUmhvSEtUQTJfdFVCOGYxRXZmOENaUVRHQWpuLThUMWtQbDNpZFQ5RllsR2pmSzFRb214TEstcUJlOUxVZ0U2OA?oc=5" target="_blank">Epcoritamab Plus Lenalidomide and Rituximab in Practice: A Focus on EPCORE FL-1</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
The Lancetgeneral

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPRFFtbnQzQTdEc0Zoa2RjT0N3dHliVnZHamVTdWdicTVjOXpCYXFJLWUyYVJBNkhuOGx4cW1QcGJIV3JUd1dlU1NmR1JMdV9IUnNWMTNJUWJPWTU2M2kwVkdLSnUwTC1NT0IwaUZ0QkVNY25yUndnQUJJdHI5QjROSkh5RW5Ea1JCcXNB?oc=5" target="_blank">Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Adding Epcoritamab to R2 in R/R Follicular Lymphoma Meets Cost-Effectiveness Tests
The American Journal of Managed Caregeneral

Adding Epcoritamab to R2 in R/R Follicular Lymphoma Meets Cost-Effectiveness Tests

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQMm1BdFUxUVZUWkFEUmk2cWl0WmtuMnFudGVuSkR4WjVNc2pYQlQwNnlKWVVZdkE5Q0k4QlIxOVMtRDNURUhXVEtoYmViMW9aVW1NOThnUmNMZUJ4Sm5EMjB2LUhIMTRxZHJzVTlpVW1wdzkzM0ZYNUpZZ0RpYUF1OG94YjZiWkh2QWN4aGl6TkhXaEFycWQxWFJEZ1FBZVpCaTRUa05xUUhEZnZS?oc=5" target="_blank">Adding Epcoritamab to R2 in R/R Follicular Lymphoma Meets Cost-Effectiveness Tests</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
Epcoritamab Plus R2 Sustains Efficacy Across Subgroups in R/R Follicular Lymphoma
Targeted Oncologytech

Epcoritamab Plus R2 Sustains Efficacy Across Subgroups in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOb2sycDJORnZMMExidWtaUXVMTWdDd2tmRTBVLXh1Zm5JV3RURHRwLVBXc1p4QmlVM1RsdzZLTUpHazktcTVfQzRPaElGaEJzdnVKRTVkUXJwUWRlamFnMm1PWDZ6UTVTZ3ZLdHY0aE5HMWhxclp5d1BGYmsyUXJtdW9tU000RlYta0MwNmRFMTE4VXpoMWdySnpraUxBeXdQVU1DTUZqNjdsbXlqVWp1WWhiQzg?oc=5" target="_blank">Epcoritamab Plus R2 Sustains Efficacy Across Subgroups in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
European Commission Approves Tepkinly Plus R2 as First Bispecific-Based Therapy for Relapsed or Refractory Follicular Lymphoma
BioPharm Internationalworld

European Commission Approves Tepkinly Plus R2 as First Bispecific-Based Therapy for Relapsed or Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMi_gFBVV95cUxQMFlpWFViN0R1eXFWTlY1dTlxMGxMOTdEWkFPVTN5NkRtN2RyS0J2czdnVE5MSDRKbTFnaExsNGx3dS1LMDQtV01wd0RiTHFrZDFsZmtsLVQ2YzhTbmtjTVBxZFJKOHY4XzNFZ0o0NjhMTVhldWxIeFZNYV83cG5FVVFUVzJITkwxRzJlaXdTVUNROC0xenpCU0lXcEpuenpMMEVvXzlQQ3Q4YncxOHc2VVZodFl6RmFUTVF1M0l3cDdHRVpFTDRCMGsyYjdhbmVyRkNzVkJ6aXpqQm9QUEFiZ0Q2dTlzM29WaXBVR0doeUR2YUZZZUhYLVJqaDVmdw?oc=5" target="_blank">European Commission Approves Tepkinly Plus R2 as First Bispecific-Based Therapy for Relapsed or Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">BioPharm International</font>

Read Full StoryMore like this
“Substantial” Reduction in Risk for Progression or Death in RR/FL with Epcoritamab Plus R2
Oncology News Centralgeneral

“Substantial” Reduction in Risk for Progression or Death in RR/FL with Epcoritamab Plus R2

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNbmZsWUtnb0hIQmVSZFl0S0JDNzE1aDRnOS1EQW5ZREozcDdVWE9wek9XbUJGc0ZjSjFfX2puR3lqcTk0YzUxV0RuLWgwTnFCM01OakRLT1dNblJsWC14X29vLVZtWTdyRzdPVXc1U2tscFNEc3ZhQThfZEhnYTBUNVhYVU5nQzEzelVISlZhZk9yZjVvS0RLNnhTck0ybWJyT2YxRmc0WUlMdlQ5cEFiUDB6enhZWmVHcEVKc1NhTEZFZ0hkVVYw?oc=5" target="_blank">“Substantial” Reduction in Risk for Progression or Death in RR/FL with Epcoritamab Plus R2</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
New Second-Line Treatment Options for Patients With Follicular Lymphoma
ASCO Daily Newsgeneral

New Second-Line Treatment Options for Patients With Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxObTNKSlNJNHpCTDdLS1RNRDlWdjAzQllwUER3TmV4VUEtb0d2NW1ZNnUyNi1wLUtsVzhTcm5oOE40blgwYWk3N0dCMU5XY2wtZnFua0Y1Y0ZMbDlvOFM4alZiNy1pd19pVkdMMUt0WmFiNFF2NVg0dlkxMVRLVEd4ckotWGJjZTctWC1LY1RSR3hpeldmNDhiSjBVU1c?oc=5" target="_blank">New Second-Line Treatment Options for Patients With Follicular Lymphoma</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
ASH 2025 News: Epcoritamab plus R2 Superior to R2 Alone for Relapsed/Refractory Follicular Lymphoma
Memorial Sloan Kettering Cancer Centergeneral

ASH 2025 News: Epcoritamab plus R2 Superior to R2 Alone for Relapsed/Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNaldlME1tSDhqaXpDZ0JPbTM3MWZxMnhHeW0wMmc5bE13aGZIc0w2NmwyMHBVaUNITDRNOUpqblVtSVRqUlNKUlcyUmUzU1plQlNIUjhrcFloUHpNdG5xdkcxTXI2VWYxcnNmWWhsdGpJNmVkekNRSTZrVWF2emd0MkNJNzlJMU1PVlRXT1NfV3BadzRhbW5qTzJoekthN2EzamV2UmhtSVhqaHRVWmRGeW1COXF6TzRQVklQcGlKczF4V0J4aW81MklUSUMwR1VkMk9R?oc=5" target="_blank">ASH 2025 News: Epcoritamab plus R2 Superior to R2 Alone for Relapsed/Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">Memorial Sloan Kettering Cancer Center</font>

Read Full StoryMore like this
Relapsed or Refractory Follicular Lymphoma Standard of Care Could Change
Medscapegeneral

Relapsed or Refractory Follicular Lymphoma Standard of Care Could Change

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPUzBVR0Y3UXBFVWJpY3JEQm4xV0RZYVJnS2l5RjZ2WFVxZGNUNW5xRW85elpuZ1lwZEhqX1E1Z2EwSUJPbk03NU1YWEpMUGpZa01DZWlLY0htMGxLTThXT3lDckVVLWJQTkJQTUc5cVBPSkxneDJvVXY0NDFSZ294ZTR4MjV0ZVFUMkVIZE5TZlZVRmMzdHlYYU9ncGZrUzFmd2lTb1NSQ2pfZw?oc=5" target="_blank">Relapsed or Refractory Follicular Lymphoma Standard of Care Could Change</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
New trial shows major survival gains with epcoritamab added to standard R2 therapy
News-Medicaltech

New trial shows major survival gains with epcoritamab added to standard R2 therapy

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQR0ZpUnFScjZCZ2I2dDFCeFFzRXdnWlZEY19RSHN6QUpNT1dNd1NzczRodE9mS3VfYmUxbHdISVJxMmJpT09zLXJIWGp1Z19Cc3BqZHZLWE5GRXFBQTMydGJNbkNGVkloMEZBUmYzSmQtNFYyVTZBczRaYnE5WElpWkFING9PNVNFeXJGeTdRSEwxZVdoNG02UXRVVDNjYThHRjFKRW5RbFFkUUJuaDFMdXhCRDJRWEhjclIzNGZDZGJwenhzbFkybzJB?oc=5" target="_blank">New trial shows major survival gains with epcoritamab added to standard R2 therapy</a>  <font color="#6f6f6f">News-Medical</font>

Read Full StoryMore like this
Primary Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab With Rituximab and Lenalidomide (R2) Versus R2 for Relapsed or Refractory Follicular Lymphoma
OncLivegeneral

Primary Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab With Rituximab and Lenalidomide (R2) Versus R2 for Relapsed or Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMilAJBVV95cUxQby1kUXlMR3F3a3ZJbWhvb2VnQzlNTngxZ2JIRDJNTi1Kci10QzE5ZTJtbmFnWUlLZ2l6OElYUHBJWW5pbk1JY19rZ1BXN015Vkt4b2VxOEZLaVVydGlqRmZTX1BrS29xQ2k1Uk44RXphdUo0YldVSFl0anFleG83MFUyMjNRRkNzbDJEakZOalFkNU1tTGpIMVIwMXNFaTQ2UXlRblVIa0tCd0lhcDFWVkFUaWNtbzVuVDk5cDRyVURkNEtzcERPZkgzNUt2Z1gzYWpaRDM4ck9saVlpZ19RWUFjOGFYbUR2RkR1alUyWko0dFVicnBaR0VsdHljT3F3VjdkRFlqYmg4UWwzV3V1dHRQTzk?oc=5" target="_blank">Primary Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab With Rituximab and Lenalidomide (R2) Versus R2 for Relapsed or Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma
CancerNetworkgeneral

Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNX0xPVjhHRVI0U19WM0pxNExGcTlLU2hjRE9qWHR4WXBJLUdtZGtEdFdpQl9qMFpnM0NIR09ZWm5mTE9WNHpOa19RWm9RTkw3SGdqVjhWeV9hdGhjSEdBUnJIV3BFX2diejdTYU91OGVIclA4Vk03TTFHV0hJQllxSWk4SVlKTXVDQlZYWThjdGN6VW5VV0U2MWRiUjBOaFZTYk1fQTBzY0ctbWk3M2tBRm8tMTk?oc=5" target="_blank">Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
AJMCgeneral

EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOTmdVM2FlcVUydnRsUnVXdm9sYmFkeXBDUjgwVjJVZzROWDdPbUVkWHowWmNIYjA1YzdBRk5CdUZaUHZacXdqeUJ3NnRFVzRLRUJ6UjNYY29CdjhUeVdzRl9OS0RiTnF0U0dqYXNsVlI1TElxSWdYLUJQaGRFYUpCbEdkcjVJRjJqN0twMWItSjA0VFBzOWdtS1RfS05fVkFNc2szd25PRE1hTjgyRGhzd1dQQzdIWHZkYVkzMg?oc=5" target="_blank">EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
FDA Approves Epcoritamab Combo and Monotherapy for Follicular Lymphoma
Oncology News Centralgeneral

FDA Approves Epcoritamab Combo and Monotherapy for Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNd05lbFZ2U1UwRVVCZVlobV93V0JHTFlaU2JiUXZ4Si1tZ0V0Rkx0dm5pa0ZPQm1rbGg2SmZnYlNkLVJ0ejJ4MFo4Qy1mc1liNXVuQ1V6U0VXNWRkTHlud2I1UkRZdndUMk1Ua0NpaG5laGxsUDZGRHVmRmZuUmxBSUIzTlIydTBqV016NThLVUtxazA4bndNcVRGTklLVmpYQzlnaG9qMTgzbkpyZkhlbjdVa1RReEhy?oc=5" target="_blank">FDA Approves Epcoritamab Combo and Monotherapy for Follicular Lymphoma</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Dr Falchi on Responses With Epcoritamab Plus R2 in R/R Follicular Lymphoma
OncLivegeneral

Dr Falchi on Responses With Epcoritamab Plus R2 in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQMDNHVDJoUjg2VjhRcWlHcjJlVlVlQjc2eHd3M3dPdEhEUTMzNDRDMWJHSVBYUnBXZS1TMlJjT2libUpvTnczRTBXSmRwYnByc2x5SGFZV3JrcHhObEFxa3ZhV3NpcDlkdmRabU1qdVE3TGFkek5KUEx5NDRtelo0RV9maGFteXVSMVNJdExqZWJsV2t6WkNLTV84UXo0d2kydWJ0d1Rn?oc=5" target="_blank">Dr Falchi on Responses With Epcoritamab Plus R2 in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line
The American Journal of Managed Caregeneral

Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPLWRua0JocEYwNjhQYUhrNGVpdm5mdDNiUGcxNHVqamRiRVNVdG96WU5xSV95YndYSDU4eVExcnRBbGFBYmpWeEV2cWlqUDhud0hSeFhsUFVOVWNOMHF5bkpUd1QtV1Ewc3V3blFPZG5FN1M3NkNSSGRYUk9ueW5vbF9wTUVsNHNic2dOTnJMeEVjM3ExaXhLbWRqREVUTm9ucEJxV1UxQ19jZ05vd0lhRFNkUXUxMzFkOEpkV2hFVQ?oc=5" target="_blank">Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
FDA Approves Epcoritamab Combo in R/R Follicular Lymphoma
CancerNetworkgeneral

FDA Approves Epcoritamab Combo in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOcnhVQ29mckdMcWYyWlJGTEhka2JDdnk0ZG1xdmppbFJVSm8wdzFBRzBjUFZsQU1qOUtLMU5HVnpjNklPRDVaR0ZWMnZTTW5uZFVEbldJbkxVQnE4cWVVbkdWQ3JqWENOY1BJZ29ndkpCM1RxaXg2R1ZHWmp4bWRQQWtLbzVCdWNyWWotcnBKUER0cnMzb2Zv?oc=5" target="_blank">FDA Approves Epcoritamab Combo in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
FDA Approves Epcoritamab for R/R Follicular Lymphoma
OncLivegeneral

FDA Approves Epcoritamab for R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxNWlFOOXI1T0tLblozVmFuQ1VySVpTOVZpTzhxMUl0RHlFTmxUc1YyTWNibXVHeUY2b0lHYzk0cGJaNUd1NEphS1J2cWdhdkpaTzUyU2tEWnZha1RBWFJ0OGRwV0RjN0xONlBxU0NDbGZ4NDNpSEZ6eS1xSWJpUWthYWktMWs4LTRC?oc=5" target="_blank">FDA Approves Epcoritamab for R/R Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Epcoritamab Plus Rituximab/Lenalidomide, Epcoritamab Maintenance Both Deliver Durable Remissions in First-Line Follicular Lymphoma
OncLivetech

Epcoritamab Plus Rituximab/Lenalidomide, Epcoritamab Maintenance Both Deliver Durable Remissions in First-Line Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOS1dud3k0d0dUbzdySTVhZmdYeFVaN3haZk9QYnAwa3VlajlxaW5VdmdyclpKOVF5MXl1LXpiaWVJNGlLTXA0Qi0xWDhiQ2FWLUNWdkVEaDJBQ2tjdDEyQkcwMWJTSnYwT0M1dEJ5SVRwbnRoS1NyQlJLWXRYM2RKRVR4RE8tV3NmaEljSjY4NVJzTzNlN09MRVl4Mk5jVFhQaGlmdDlOQ05xQV9WNlVKZkFlTWRjLWZnaTQxM0ZuU2U3UUJLN041UnBwbm91bTVuQVFOcHN0Uk15NnBGcnVWcklqMEp6UVE3TTFGWXdRSQ?oc=5" target="_blank">Epcoritamab Plus Rituximab/Lenalidomide, Epcoritamab Maintenance Both Deliver Durable Remissions in First-Line Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approves Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma
Oncology Nursing Newsgeneral

FDA Approves Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPVmduU3FoZVhONXFlLWF4ODZGeks1SkJ3Q0tZUzZLTjZMTHFFZFdlMWp1VG9kcWVfM1ppRjktOXU3eHQwRjM0aHNUd1pSa1NQUlc2R0RldWJGVmNGTEI0ZzZyeDhmaHNjMUZCeTBFSElfb01tSno2bFFpLXBsMk1mWTd1OGc1LXlXRHdjMklWRzhPR21wckhqQUFFRGVPQ2k2cGk2VTR6T2tRZDIwM0htTUdSRTZMUQ?oc=5" target="_blank">FDA Approves Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
Genmab Announces TEPKINLY® (epcoritamab) in Combination
GlobeNewswireworld

Genmab Announces TEPKINLY® (epcoritamab) in Combination

<a href="https://news.google.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?oc=5" target="_blank">Genmab Announces TEPKINLY® (epcoritamab) in Combination</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Best First-Line Regimen for Follicular Lymphoma May Be Predicted by Just 2 Genes
Oncology News Centralgeneral

Best First-Line Regimen for Follicular Lymphoma May Be Predicted by Just 2 Genes

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQYVBSUlNzeGxxYmxodjlMdnNfNW5wb3FqR09mcENySVVwNTYzRmxORzRic3FRbGdLS2hSeU0yd2V6cXJxZEthVkJ2cmZhMzd3ZU9FVzJDS1RVVlluaEtSek1ETmF0NDBhUlh2NDREYm52dlV3NFlEeGxQdFZWMmNudmU3b1Y3ZXpDYWNFZ2hkT3E3S2U4bU1CbHVpa3FPcnBYVVNYdWotMmVMdnEtZ184SmRPYUYxVnB2SHFaYQ?oc=5" target="_blank">Best First-Line Regimen for Follicular Lymphoma May Be Predicted by Just 2 Genes</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Spotlight on Follicular Lymphoma Therapies: Highlights From ASH 2024
Cancer Therapy Advisorgeneral

Spotlight on Follicular Lymphoma Therapies: Highlights From ASH 2024

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOVDRGWUtsLUNPS25sZndBazBoM3JmY2d6YXcwWm9Ebkl5TzBubVZnUnozb3NYbERNb2YtTjJ3X3hFN1Z2dnV0dDZ2RVJGVmM3ekltVllGdjg5MWg0dTY5TXVCbi1HSi1zVFJPZktVSTlPbjZxMnR4NDFRWmh6MDI3NVk2NGpRUjhlNk9fcVAwUzU2MU9VSTFBckJiRFE?oc=5" target="_blank">Spotlight on Follicular Lymphoma Therapies: Highlights From ASH 2024</a>  <font color="#6f6f6f">Cancer Therapy Advisor</font>

Read Full StoryMore like this
"Epcoritamab Plus R2 in Fo" — Live Google News Trends & Headlines